Brief: Argent Biopharma And Auscann Enters Strategic Heads Of Agreement
15/04/2025 02:29
April 15 (Reuters) - Argent BioPharma Ltd RGT.AX: CO, AUSCANN ENTERED STRATEGIC HEADS OF AGREEMENT TO ACCELERATE CANNABINOID-BASED PHARMACEUTICAL DEVELOPMENT AUSCANN WILL LICENSE ARGENT BIOPHARMA'S CANNEPIL CMC AND DOSSIER FOR NON-EPILEPSY RELATED PHARMACEUTICAL PROGRAMS Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group